Biovie Inc (BIVI)

$1.31 -0.01 (-0.76%)
Market Cap 10.18M
Revenue (ttm) 0.00
Net Income (ttm) -17.54M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 70,500
Avg Vol 80,610
Day's Range N/A - N/A
Shares Out 7.54M
Stochastic %K 4%
Beta 0.72
Analysts Strong Buy
Price Target $12.00

Company Profile

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as fo...

Industry: Biotechnology
Sector: Healthcare
Phone: 775 888 3162
Address:
680 W. Nye Lane, Suite 204, Carson City, United States
Thorilium
Thorilium May. 13 at 2:46 PM
$BIVI going to fall below 1
0 · Reply
jckdg
jckdg May. 13 at 12:22 PM
$BIVI They announced their earnings on May 11. Check their web site.
0 · Reply
Rod75b15
Rod75b15 May. 13 at 10:59 AM
$BIVI
0 · Reply
TJ12000
TJ12000 May. 12 at 4:20 PM
$BIVI
0 · Reply
Mkt_predictor
Mkt_predictor May. 12 at 1:58 PM
$BIVI 💩💩💩💩💩💩
0 · Reply
Thorilium
Thorilium May. 12 at 6:06 AM
$BIVI this sounds and moves like another R/S is coming up...no news and waiting game Auwch
1 · Reply
TJ12000
TJ12000 May. 11 at 7:41 PM
$BIVI Kong after hours trying to extend the scam
0 · Reply
Sensore
Sensore May. 11 at 6:24 PM
$BIVI ..
0 · Reply
Mkt_predictor
Mkt_predictor May. 11 at 6:15 PM
$BIVI Total dumpster fire. Parkinson's data must be bad.
0 · Reply
MBWallingford
MBWallingford May. 10 at 7:35 PM
$BIVI terren pizer and any company he is part of is a complete waste of money. Snake oil salesman.
0 · Reply
Latest News on BIVI
BioVie Transcript: KOL event

May 7, 2026, 2:00 PM EDT - 6 days ago

BioVie Transcript: KOL event

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026

Apr 27, 2026, 8:00 AM EDT - 16 days ago

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026

BioVie Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators

Apr 16, 2026, 11:30 AM EDT - 27 days ago

BioVie Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators

BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting

Apr 14, 2026, 8:00 AM EDT - 4 weeks ago

BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting

BioVie Transcript: Status update

Mar 4, 2026, 4:15 PM EST - 2 months ago

BioVie Transcript: Status update

Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights

Feb 12, 2026, 12:12 PM EST - 3 months ago

Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights

BioVie completes enrollment in Phase 2 SUNRISE-PD trial

2026-01-08T13:43:03.000Z - 4 months ago

BioVie completes enrollment in Phase 2 SUNRISE-PD trial

HALPER SADEH LLC ENCOURAGES BIOVIE INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Dec 24, 2025, 2:05 PM EST - 5 months ago

HALPER SADEH LLC ENCOURAGES BIOVIE INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Join Biovie's Exclusive Live Investor Webinar and Q&A Session on December 9

Nov 19, 2025, 8:00 AM EST - 6 months ago

Join Biovie's Exclusive Live Investor Webinar and Q&A Session on December 9

BioVie Transcript: AGM 2025

Nov 10, 2025, 2:00 PM EST - 6 months ago

BioVie Transcript: AGM 2025

BioVie Transcript: Investor Update

Oct 8, 2025, 4:15 PM EDT - 7 months ago

BioVie Transcript: Investor Update

BioVie to Host Live Investor Webinar and Q&A on Oct. 8

Sep 26, 2025, 8:00 AM EDT - 8 months ago

BioVie to Host Live Investor Webinar and Q&A on Oct. 8

BioVie price target adjusted to $12 from $6 at Brookline

2025-08-29T17:10:18.000Z - 9 months ago

BioVie price target adjusted to $12 from $6 at Brookline

BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes

Aug 13, 2025, 4:05 PM EDT - 9 months ago

BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes

Why Is BioVie Stock (BIVI) Down 50% Today?

2025-08-09T00:43:00.000Z - 9 months ago

Why Is BioVie Stock (BIVI) Down 50% Today?

BioVie 6M share Secondary priced at $2.00

2025-08-08T00:50:12.000Z - 9 months ago

BioVie 6M share Secondary priced at $2.00

BioVie Inc. Announces Pricing of $12 Million Public Offering

Aug 7, 2025, 8:43 PM EDT - 9 months ago

BioVie Inc. Announces Pricing of $12 Million Public Offering

BioVie presents data on Bezisterim at WCAG-2025

2025-07-24T12:20:32.000Z - 10 months ago

BioVie presents data on Bezisterim at WCAG-2025

BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology

Jul 24, 2025, 8:00 AM EDT - 10 months ago

BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology

BioVie appoints Amy Chappell, Kameel Farag to board of directors

2025-07-22T12:11:30.000Z - 10 months ago

BioVie appoints Amy Chappell, Kameel Farag to board of directors

BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors

Jul 22, 2025, 8:00 AM EDT - 10 months ago

BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors

BioVie reports results from bezisterim Phase 3 NM101 study

2025-07-09T12:22:03.000Z - 11 months ago

BioVie reports results from bezisterim Phase 3 NM101 study

BioVie Inc. trading halted, news pending

2025-07-03T20:50:10.000Z - 11 months ago

BioVie Inc. trading halted, news pending

BioVie announces poster on patient-centric accessibility of SUNRISE-PD trial

2025-06-26T12:16:13.000Z - 11 months ago

BioVie announces poster on patient-centric accessibility of SUNRISE-PD trial

BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)

Jun 26, 2025, 8:00 AM EDT - 11 months ago

BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)

BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress

Jun 24, 2025, 4:05 PM EDT - 11 months ago

BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress

BioVie Transcript: AGM 2025

Jun 23, 2025, 5:00 PM EDT - 11 months ago

BioVie Transcript: AGM 2025

BioVie Transcript: Status Update

May 28, 2025, 12:00 PM EDT - 1 year ago

BioVie Transcript: Status Update

BioVie announces first patient enrollment in Phase 2 ADDRESS-LC trial

2025-05-15T12:11:23.000Z - 1 year ago

BioVie announces first patient enrollment in Phase 2 ADDRESS-LC trial

BioVie to host KOL event on Phase 2 study of bezisterim

2025-05-14T11:57:58.000Z - 1 year ago

BioVie to host KOL event on Phase 2 study of bezisterim

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025

May 14, 2025, 7:30 AM EDT - 1 year ago

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025

BioVie to present design of Phase 2 SUNRISE-PD trial

2025-05-07T12:24:31.000Z - 1 year ago

BioVie to present design of Phase 2 SUNRISE-PD trial

BioVie announces formation of Corporate Advisory Board

2025-05-05T12:27:31.000Z - 1 year ago

BioVie announces formation of Corporate Advisory Board

BioVie initiates SUNRISE-PD trial assessing Bezisterim

2025-04-16T12:14:13.000Z - 1 year ago

BioVie initiates SUNRISE-PD trial assessing Bezisterim

BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025

Mar 27, 2025, 8:00 AM EDT - 1 year ago

BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025

BioVie initiated with a Buy at Brookline

2025-03-19T09:00:10.000Z - 1 year ago

BioVie initiated with a Buy at Brookline

BioVie initiated with a Buy at Brookline

2025-03-19T07:20:32.000Z - 1 year ago

BioVie initiated with a Buy at Brookline

BioVie Transcript: AGM 2024

Nov 7, 2024, 1:00 PM EST - 1 year ago

BioVie Transcript: AGM 2024

UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 28, 2024, 4:10 PM EDT - 1 year ago

UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 28, 2024, 3:13 PM EDT - 1 year ago

BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement

Oct 24, 2024, 4:10 PM EDT - 1 year ago

BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement

BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Oct 23, 2024, 3:24 PM EDT - 1 year ago

BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin

Oct 15, 2024, 8:00 AM EDT - 1 year ago

BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin

BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Oct 11, 2024, 9:00 AM EDT - 1 year ago

BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

GENE

BioVie Inc. Announces Closing of Public Offering

Sep 25, 2024, 4:05 PM EDT - 1 year ago

BioVie Inc. Announces Closing of Public Offering

BioVie Inc. Announces Pricing of Public Offering

Sep 23, 2024, 10:26 PM EDT - 1 year ago

BioVie Inc. Announces Pricing of Public Offering

BioVie Inc. Announces Proposed Public Offering

Sep 23, 2024, 4:05 PM EDT - 1 year ago

BioVie Inc. Announces Proposed Public Offering

BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID

Sep 16, 2024, 8:00 AM EDT - 1 year ago

BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID

BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID

Sep 3, 2024, 8:00 AM EDT - 1 year ago

BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID

BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting

Aug 27, 2024, 8:45 AM EDT - 1 year ago

BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting

BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson's Disease

Aug 8, 2024, 6:00 AM EDT - 1 year ago

BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson's Disease

BioVie Inc. Announces Reverse Stock Split

Aug 6, 2024, 4:40 PM EDT - 1 year ago

BioVie Inc. Announces Reverse Stock Split

BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jul 5, 2024, 9:00 AM EDT - 2 years ago

BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

BIAF

BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jun 21, 2024, 9:00 AM EDT - 2 years ago

BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

MOB

BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at 2024 ATMRD Congress

Jun 20, 2024, 8:00 AM EDT - 2 years ago

BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at 2024 ATMRD Congress

Join BioVie's Exclusive Live Investor Webinar and Q&A Session on June 26

Jun 12, 2024, 8:24 AM EDT - 2 years ago

Join BioVie's Exclusive Live Investor Webinar and Q&A Session on June 26

BioVie's Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson's Disease Patients

May 22, 2024, 8:00 AM EDT - 2 years ago

BioVie's Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson's Disease Patients

BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID

Apr 29, 2024, 8:00 AM EDT - 2 years ago

BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID

BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer's Disease and Biomarker Endpoints

Apr 25, 2024, 8:00 AM EDT - 2 years ago

BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer's Disease and Biomarker Endpoints

BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation

Apr 18, 2024, 8:00 AM EDT - 2 years ago

BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation

Thorilium
Thorilium May. 13 at 2:46 PM
$BIVI going to fall below 1
0 · Reply
jckdg
jckdg May. 13 at 12:22 PM
$BIVI They announced their earnings on May 11. Check their web site.
0 · Reply
Rod75b15
Rod75b15 May. 13 at 10:59 AM
$BIVI
0 · Reply
TJ12000
TJ12000 May. 12 at 4:20 PM
$BIVI
0 · Reply
Mkt_predictor
Mkt_predictor May. 12 at 1:58 PM
$BIVI 💩💩💩💩💩💩
0 · Reply
Thorilium
Thorilium May. 12 at 6:06 AM
$BIVI this sounds and moves like another R/S is coming up...no news and waiting game Auwch
1 · Reply
TJ12000
TJ12000 May. 11 at 7:41 PM
$BIVI Kong after hours trying to extend the scam
0 · Reply
Sensore
Sensore May. 11 at 6:24 PM
$BIVI ..
0 · Reply
Mkt_predictor
Mkt_predictor May. 11 at 6:15 PM
$BIVI Total dumpster fire. Parkinson's data must be bad.
0 · Reply
MBWallingford
MBWallingford May. 10 at 7:35 PM
$BIVI terren pizer and any company he is part of is a complete waste of money. Snake oil salesman.
0 · Reply
TJ12000
TJ12000 May. 10 at 5:53 PM
$BIVI Kong funneling ur money to the other gypsies
0 · Reply
Duskfall
Duskfall May. 9 at 3:33 PM
Tnya +44% the others will follow shortly📈✅ https://youtu.be/__7K3FNiWeo?si=c5vbBa7753Kcfsap $BIVI $SES $CRMD $TNYA $IMMP
0 · Reply
TJ12000
TJ12000 May. 9 at 12:51 PM
$BIVI pay for the fraud d Kong….thieving gypsy
0 · Reply
Parobolicbatman
Parobolicbatman May. 8 at 9:55 PM
$BIVI expected earnings?
0 · Reply
TJ12000
TJ12000 May. 8 at 7:19 PM
$BIVI Look in the mirror is step 1....then state I was bamboozled by greaseball kong and his tribe of gypsies...then join the numerous class action lawsuits and shut this bitch down!
0 · Reply
Duskfall
Duskfall May. 8 at 5:19 PM
$BIVI Fool.. this is now a great dip buying opportunity💯
0 · Reply
TJ12000
TJ12000 May. 8 at 4:36 PM
$BIVI bIScAMiUm molecule
0 · Reply
Sensore
Sensore May. 8 at 3:57 PM
$BIVI ..
0 · Reply
TJ12000
TJ12000 May. 8 at 3:05 PM
$BIVI new bivi facility now open in st Augustine FL!!!
0 · Reply
michaels2012
michaels2012 May. 8 at 2:36 PM
$BIVI didn’t they have some event yesterday to provide an update on phase 2 bezisterim? Guess it didn’t mean much.
0 · Reply
TJ12000
TJ12000 May. 8 at 12:26 PM
$BIVI gypsy run company
0 · Reply
_2025
_2025 May. 8 at 10:34 AM
$BIVI @TJ12000 you are an idiot get a life
1 · Reply